Home › Upcoming votes › iSpecimen Inc.
This meeting took place on October 30, 2026. Official results not yet filed. Companies report them on Form 8-K, usually within four business days of the meeting; they will appear here once they have been read.
The deadline as the proxy statement states it: “vote until 11:59 p.m. Eastern Time on October 29, 2026”. Shares held through a bank, a broker or a company plan can have a different deadline; the voting instruction form says.
Read the proxy statement on EDGAR
Ballot read from the proxy statement and checked. As listed in iSpecimen Inc.’s proxy statement, with the board’s recommendation on each item.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | To approve, for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of shares of common stock underlying Pre-Funded Warrants and any additional shares issuable pursuant to the most-fa | Board | For | — |
| 2 | BROKER DISCRETIONARY VOTING ON PROPOSAL NO. | Board | For | — |
| 3 | To approve, for purposes of Nasdaq Listing Rule 5635(d), the issuance of shares of common stock upon conversion, exercise or exchange of convertible or equity-linked securities that may be issued duri | Board | For | — |
| 4 | To approve the Asset Acquisition (as defined in the accompanying Proxy Statement), including the issuance of shares of Common Stock as partial consideration therefor, pursuant to the Asset Purchase Ag | Board | For | — |
| 5 | To approve the adjournment of the Special Meeting, if necessary or appropriate, to solicit additional proxies if there are not sufficient votes at the time of the Special Meeting to approve Proposal N Adjournment |
Board | For | — |
From iSpecimen Inc.’s Form 8-K, filed November 3, 2025, for the meeting held October 30, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| 1. Approval of Reverse Stock Split | 97% | Approved |
| 2. Approval of Increase in Authorized Shares | 96% | Approved |
| 3. Approval Pursuant to Nasdaq Listing Rule 5635(d) - Private Financing Transactions | 96% | Approved |
| 4. Approval of Amendment to Certain Outstanding Convertible Securities | 98% | Approved |
| 5. Approval Pursuant to Nasdaq Listing Rule 5635(d) - Equity Line of Credit | 96% | Approved |
| 6. Other Business | 97% | Approved |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.